



# Ovary, Fallopian Tube and Primary Peritoneal Carcinoma Histopathology Reporting Guide

Family/Last name Date of birth Given name(s) Patient identifiers Date of request Accession/Laboratory number Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.  indicates multi-select values  indicates single select values

SCOPE OF THIS DATASET

**CLINICAL INFORMATION** (select all that apply) 

- Information not provided  
 Known gene predisposition (e.g., *BRCA1*, *BRCA2*, Lynch syndrome), *specify*

- 
- Prior neoadjuvant therapy,
- specify*

- 
- Other,
- specify*

**SPECIMEN(S) SUBMITTED** (select all that apply) 

- Not specified  
 Ovary  
 Left  Right  Laterality not specified  
 Ovarian cystectomy  
 Left  Right  Laterality not specified  
 Fallopian tube  
 Left  Right  Laterality not specified  
 Uterus  
 Cervix  
 Omentum  
 Peritoneal biopsies  
 Peritoneal washings/peritoneal fluid  
 Lymph nodes, *specify site(s)*

- 
- Other,
- specify*

**SPECIMEN INTEGRITY** (select all that apply) 

(Required only if ovary(ies)/fallopian tube(s) are submitted)

**Left ovary**

- Ovarian capsule intact  
 Ovarian capsule ruptured  
 Information not provided  
 Preoperatively  
 Intraoperatively  
 Tumour on surface  
 Fragmented specimen  
 Other, *specify*

**Right ovary**

- Ovarian capsule intact  
 Ovarian capsule ruptured  
 Information not provided  
 Preoperatively  
 Intraoperatively  
 Tumour on surface  
 Fragmented specimen  
 Other, *specify*

**Left fallopian tube**

- Serosa intact  
 Serosa ruptured  
 Information not provided  
 Preoperatively  
 Intraoperatively  
 Tumour on serosal surface  
 Fragmented specimen  
 Other, *specify*

**Right fallopian tube**

- Serosa intact  
 Serosa ruptured  
 Information not provided  
 Preoperatively  
 Intraoperatively  
 Tumour on serosal surface  
 Fragmented specimen  
 Other, *specify*

**TUMOUR SITE** (select all that apply) 

- No macroscopically visible tumour  
 Indeterminate  
 Ovary  
 Left  Right  Laterality not specified  
 Fallopian tube  
 Left  Right  Laterality not specified  
 Fimbrial  Fimbrial  
 Non-fimbrial  Non-fimbrial  
 Peritoneum  
 Other, *specify*

**TUMOUR DIMENSIONS**

(If separate tumours specify dimensions for each site)

 x  x **MACROSCOPIC DESCRIPTION OF OMENTUM**

(Required only if omentum submitted)

**Omentum dimensions** x  x **Omental involvement**

- Not involved  
 Involved

Maximum dimension of largest tumour deposit

**BLOCK IDENTIFICATION KEY** 

(List overleaf or separately with an indication of the nature and origin of all tissue blocks)

**HISTOLOGICAL TUMOUR TYPE** (select all that apply) 

(Value list based on the World Health Organization Classification of Female Genital Tumours (2020))

- Serous borderline tumour
- Low grade serous carcinoma
- High grade serous carcinoma
- Mucinous borderline tumour
- Mucinous carcinoma
- Endometrioid borderline tumour
- Endometrioid carcinoma
- Clear cell borderline tumour
- Clear cell carcinoma
- Seromucinous borderline tumour
- Borderline Brenner tumour
- Malignant Brenner tumour
- Mesonephric-like adenocarcinoma
- Carcinoma, undifferentiated
- Dedifferentiated carcinoma
- Carcinosarcoma
- Mixed carcinoma
- Other, specify

**PATTERN OF INVASION** 

(Applicable for mucinous carcinomas only)

- Expansile
- Infiltrative/destructive

**CARCINOSARCOMA COMPONENTS** (select all that apply) 

Epithelial

Percentage  %

List components

Sarcomatous

Percentage  %

Type  Homologous  Heterologous

List components

**HISTOLOGICAL TUMOUR GRADE** 

**Endometrioid carcinomas**

- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated

**Mucinous carcinomas**

- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated

**BORDERLINE TUMOUR - SPECIAL FEATURES** 

(Applicable only if borderline tumour is identified)

**Micropapillary architecture for serous borderline tumour** (at least 5 mm in one dimension)

- Not identified
- Present

**Microinvasion** (upper limit 5 mm)

- Not identified
- Present

**Intraepithelial carcinoma for mucinous borderline tumour**

- Not identified
- Present

**Implants for serous and seromucinous borderline tumour** (select all that apply)

- Non-invasive implants
  - Not identified
  - Present
    - Epithelial
    - Desmoplastic
- Site(s)  Pelvic  Abdominal

- Invasive implants/Extra-ovarian low grade serous carcinoma
  - Not identified
  - Present
    - Site(s)  Pelvic  Abdominal

- Indeterminate
  - Not identified
  - Present
    - Site(s)  Pelvic  Abdominal

**SEROUS TUBAL INTRAEPITHELIAL CARCINOMA (STIC)** 

(Required only if fallopian tube(s) are submitted)

**Left fallopian tube**

- Cannot be assessed
- Not identified
- Present (select all that apply)
  - Fimbrial
  - Non-fimbrial

**Right fallopian tube**

- Cannot be assessed
- Not identified
- Present (select all that apply)
  - Fimbrial
  - Non-fimbrial

**HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT** 

**Left ovary**

- Not applicable
- Cannot be assessed
- Not involved
- Involved

**Right ovary**

- Not applicable
- Cannot be assessed
- Not involved
- Involved

**Left fallopian tube**

- Not applicable
- Cannot be assessed
- Not involved
- Involved

**Right fallopian tube**

- Not applicable
- Cannot be assessed
- Not involved
- Involved

**Uterus**

- Not applicable
- Cannot be assessed
- Not involved
- Involved (select all that apply)
  - Site(s)  Myometrium
  - Endometrium
  - Cervix

**Omentum**

- Not applicable
- Cannot be assessed
- Not involved
- Involved
  - Level of involvement
    - Macroscopic
    - Microscopic

**Peritoneum (including uterine serosa)**

- Not applicable
- Cannot be assessed
- Not involved
- Involved (select all that apply)
  - Site(s)  Pelvis, *specify site(s)*
  - Abdomen, *specify site(s)*

**Other involved organs(s)/sites(s), specify**

  


**PERITONEAL CYTOLOGY** 

- Not submitted
- Indeterminate
- Positive
- Negative

**RESPONSE TO NEOADJUVANT THERAPY** 

- Cannot be assessed
- No prior treatment
- No definite or minimal response identified (chemotherapy response score (CRS 1))
- Moderate response identified (CRS 2)
- Marked response with no or minimal residual cancer (CRS 3)

**LYMPH NODE STATUS** 

- Cannot be assessed
- No nodes submitted or found
- Not involved
- Involved (select all that apply)

**Regional**

**Left pelvic**

Number of nodes examined<sup>a</sup>

Number of positive nodes<sup>a</sup>

**Right pelvic**

Number of nodes examined<sup>a</sup>

Number of positive nodes<sup>a</sup>

**Para-aortic**

Number of nodes examined<sup>a</sup>

Number of positive nodes<sup>a</sup>

**Maximum dimension of largest deposit in regional node**  mm

**Non-regional**

**Site 1**

Number of nodes examined<sup>a</sup>

Number of positive nodes<sup>a</sup>

**Site 2**

Number of nodes examined<sup>a</sup>

Number of positive nodes<sup>a</sup>

<sup>a</sup> In some cases it may not be possible to record the actual number of nodes due to fragmentation of the specimen.

**COEXISTENT PATHOLOGY/PRECURSOR LESIONS** 

- None identified
- Present, *specify*

**ANCILLARY STUDIES** 

- Not performed
- Performed (select all that apply)

**Immunohistochemistry, specify test(s) and result(s)**

  


**Molecular findings, specify test(s) and result(s)**

  


**Other, specify test(s) and result(s)**

**ANCILLARY STUDIES (Cont.)** 

**Representative blocks for ancillary studies**, specify those blocks best representing tumour and/or normal tissue for further study

**PROVISIONAL PATHOLOGICAL STAGING** **FIGO (2014 edition)<sup>b</sup>****Site of primary tumour**

- Primary tumour, ovary (OV)
- Primary tumour, fallopian tube (FT)
- Primary tumour, peritoneum (P)
- Undesignated: site of primary tumour cannot be assessed (X)
- I Tumour is confined to ovaries or fallopian tube(s)
  - IA Tumour limited to 1 ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
  - IB Tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumour on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
  - IC Tumour limited to 1 or both ovaries or fallopian tubes, with any of the following:
    - IC1 Surgical spill
    - IC2 Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
    - IC3 Malignant cells in the ascites or peritoneal washings
- II Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer
  - IIA Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
  - IIB Extension to other pelvic intraperitoneal tissues
- III Tumour involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
  - IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven):
    - IIIA1(i) Metastasis up to 10 mm in greatest dimension
    - IIIA1(ii) Metastasis more than 10 mm in greatest dimension
  - IIIA2 Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
  - IIIB Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes
  - IIIC Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)
- IV Distant metastasis excluding peritoneal metastases
  - IVA Pleural effusion with positive cytology
  - IVB Parenchymal metastases and metastases to extra abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)

<sup>b</sup> Reprinted from *Int J Gynaecol Obstet.*, Volume 124, Part 1 and FIGO Committee on Gynecologic Oncology, *Staging classification for cancer of the ovary, fallopian tube, and peritoneum*, pages 1-5, 2014, with permission from Wiley.

**TNM Staging (UICC TNM 8<sup>th</sup> edition 2016)<sup>c</sup>****TNM Descriptors** (only if applicable) (select all that apply)

- m - multiple primary tumours
- r - recurrent
- y - post-therapy

**Primary tumour (pT)**

- TX Primary tumour can not be assessed
- T0 No evidence of primary tumour
- T1 Tumour limited to the ovaries (one or both) or fallopian tube(s)
  - T1a Tumour limited to one ovary (capsule intact) or fallopian tube; capsule intact, no tumor on ovarian surface or fallopian tube surface; no malignant cells in ascites or peritoneal washings
  - T1b Tumour limited to both ovaries or fallopian tubes; capsule intact, no tumour on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings
  - T1c Tumour limited to one or both ovaries or fallopian tubes with any of the following:
    - T1c1 Surgical spill
    - T1c2 Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
    - T1c3 Malignant cells in ascites or peritoneal washings
- T2 Tumour involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer
  - T2a Extension and/or implants on uterus and/or fallopian tube(s) and/or ovary(ies)
  - T2b Extension to other pelvic tissues, including bowel within the pelvis
- T3 and/or N1 Tumour involves one or both ovaries or fallopian tubes or primary peritoneal carcinoma with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes

**Regional lymph nodes (pN)**

- N1 Retroperitoneal lymph node metastasis only
  - N1a Lymph node metastasis not more than 10 mm in greatest dimension
  - N1b Lymph node metastasis more than 10 mm in greatest dimension
- T3a any N Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without retroperitoneal lymph node, including bowel involvement
- T3b any N Macroscopic peritoneal metastasis beyond pelvic brim 2 cm, or less in greatest dimension, including bowel involvement outside the pelvis with or without retroperitoneal nodes
- T3c any N Peritoneal metastasis beyond pelvic brim more than 2 cm in greatest dimension and/or retroperitoneal lymph node metastasis (includes extension of tumour to capsule of liver and spleen without parenchymal involvement of either organ)

<sup>c</sup> Reproduced with permission. Source: *UICC TNM Classification of Malignant Tumours, 8<sup>th</sup> Edition*, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley (incorporating any errata published up until 6<sup>th</sup> October 2020).